{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:19:33Z","timestamp":1790518773981,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R026416\/1"],"award-info":[{"award-number":["MR\/R026416\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["217112\/Z\/19\/Z"],"award-info":[{"award-number":["217112\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/15\/33\/31608"],"award-info":[{"award-number":["FS\/15\/33\/31608"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003784","name":"Great Ormond Street Hospital for Children","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.omtm.2020.07.001","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T20:42:49Z","timestamp":1594068169000},"page":"558-570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Lentiviral Hematopoietic Stem Cell Gene Therapy Rescues Clinical Phenotypes in a Murine Model of Pompe Disease"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3185-5055","authenticated-orcid":false,"given":"Giuseppa","family":"Piras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Montiel-Equihua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Ka Agnes","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slawomir","family":"Wantuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Stuckey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Prunty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Phadke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Partida-Gaytan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Leon-Rico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Whitmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Calero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Santilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian J.","family":"Thrasher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Bobby","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2020.07.001_bib1","first-page":"3389","article-title":"Glycogen storage disease type II: acid \u03b1-glucosidase (acid maltase) deficiency","volume":"Vol. 3","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.omtm.2020.07.001_bib2","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/s41467-017-01263-3","article-title":"Structure of human lysosomal acid \u03b1-glucosidase-a guide for the treatment of Pompe disease","volume":"8","author":"Roig-Zamboni","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2020.07.001_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","article-title":"Pompe disease: from pathophysiology to therapy and back again","volume":"6","author":"Lim","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.omtm.2020.07.001_bib4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","article-title":"Pompe disease: early diagnosis and early treatment make a difference","volume":"54","author":"Chien","year":"2013","journal-title":"Pediatr. Neonatol."},{"key":"10.1016\/j.omtm.2020.07.001_bib5","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.1073\/pnas.0902534106","article-title":"Neural deficits contribute to respiratory insufficiency in Pompe disease","volume":"106","author":"DeRuisseau","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"23, Suppl 2","key":"10.1016\/j.omtm.2020.07.001_bib6","first-page":"S12","article-title":"Management and treatment of glycogenosis type II","volume":"71","author":"Bembi","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2020.07.001_bib7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.21037\/atm.2019.04.49","article-title":"An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond","volume":"7","author":"Korlimarla","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.omtm.2020.07.001_bib8","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1212\/01.WNL.0000165979.46537.56","article-title":"Disease severity in children and adults with Pompe disease related to age and disease duration","volume":"64","author":"Hagemans","year":"2005","journal-title":"Neurology"},{"issue":"23, Suppl 2","key":"10.1016\/j.omtm.2020.07.001_bib9","first-page":"S4","article-title":"Diagnosis of glycogenosis type II","volume":"71","author":"Bembi","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2020.07.001_bib10","doi-asserted-by":"crossref","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2020.07.001_bib11","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/iub.529","article-title":"New insights into therapeutic options for Pompe disease","volume":"63","author":"Richard","year":"2011","journal-title":"IUBMB Life"},{"key":"10.1016\/j.omtm.2020.07.001_bib12","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/ppul.24621","article-title":"Pulmonary outcome measures in long-term survivors of infantile Pompe disease on enzyme replacement therapy: A case series","volume":"55","author":"ElMallah","year":"2020","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.omtm.2020.07.001_bib13","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41436-019-0738-0","article-title":"Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature","volume":"22","author":"Khan","year":"2020","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtm.2020.07.001_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2020.07.001_bib15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/atm.2019.05.02","article-title":"Liver depot gene therapy for Pompe disease","volume":"7","author":"Kishnani","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.omtm.2020.07.001_bib16","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes","volume":"24","author":"Smith","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2020.07.001_bib17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3389\/fimmu.2014.00350","article-title":"Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions","volume":"5","author":"Basner-Tschakarjan","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2020.07.001_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/JND-190426","article-title":"Advancements in AAV-mediated gene therapy for Pompe disease","volume":"7","author":"Salabarria","year":"2020","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtm.2020.07.001_bib19","doi-asserted-by":"crossref","first-page":"14018","DOI":"10.1038\/mtm.2014.18","article-title":"Assessment of toxicity and biodistribution of recombinant AAV8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease","volume":"1","author":"Wang","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2020.07.001_bib20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1089\/hum.2005.16.68","article-title":"Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II","volume":"16","author":"Cresawn","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2020.07.001_bib21","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2020.07.001_bib22","doi-asserted-by":"crossref","first-page":"eaam6375","DOI":"10.1126\/scitranslmed.aam6375","article-title":"Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid \u03b1-glucosidase","volume":"9","author":"Puzzo","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2020.07.001_bib23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.omtm.2018.11.002","article-title":"AAV gene transfer with tandem promoter design prevents anti-transgene immunity and provides persistent efficacy in neonate Pompe mice","volume":"12","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2020.07.001_bib24","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ymthe.2006.06.007","article-title":"Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning","volume":"14","author":"Gaspar","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.07.001_bib25","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.stem.2017.10.010","article-title":"Hematopoietic stem cell gene therapy: progress and lessons learned","volume":"21","author":"Morgan","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.omtm.2020.07.001_bib26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3389\/fped.2019.00443","article-title":"Autologous stem-cell-based gene therapy for inherited disorders: state of the art and perspectives","volume":"7","author":"Staal","year":"2019","journal-title":"Front Pediatr."},{"key":"10.1016\/j.omtm.2020.07.001_bib27","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.omtm.2020.07.001_bib28","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"R1","key":"10.1016\/j.omtm.2020.07.001_bib29","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1093\/hmg\/ddr142","article-title":"Gene therapy for leukodystrophies","volume":"20","author":"Biffi","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2020.07.001_bib30","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.omtm.2020.07.001_bib31","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2020.07.001_bib32","doi-asserted-by":"crossref","first-page":"58ra84","DOI":"10.1126\/scitranslmed.3001522","article-title":"Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy","volume":"2","author":"Gentner","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2020.07.001_bib33","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1073\/pnas.1323155111","article-title":"Platelets are efficient and protective depots for storage, distribution, and delivery of lysosomal enzyme in mice with Hurler syndrome","volume":"111","author":"Dai","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2020.07.001_bib34","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1089\/hum.2016.068","article-title":"Preclinical testing of the safety and tolerability of lentiviral vector-mediated above-normal alpha-l-iduronidase expression in murine and human hematopoietic cells using toxicology and biodistribution good laboratory practice studies","volume":"27","author":"Visigalli","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2020.07.001_bib35","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1182\/blood-2010-04-278234","article-title":"Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model","volume":"116","author":"Visigalli","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2020.07.001_bib36","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/hum.2014.158","article-title":"hematopoietic stem cell gene therapy corrects neuropathic phenotype in murine model of mucopolysaccharidosis type II","volume":"26","author":"Wakabayashi","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2020.07.001_bib37","doi-asserted-by":"crossref","first-page":"19958","DOI":"10.1073\/pnas.0908528106","article-title":"Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome","volume":"106","author":"Wang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2020.07.001_bib38","doi-asserted-by":"crossref","first-page":"e8730","DOI":"10.15252\/emmm.201708730","article-title":"Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms","volume":"10","author":"Gleitz","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2020.07.001_bib39","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.omtm.2019.04.001","article-title":"Pre-clinical safety and efficacy of lentiviral vector-mediated ex\u00a0vivo stem cell gene therapy for the treatment of mucopolysaccharidosis IIIA","volume":"13","author":"Ellison","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2020.07.001_bib40","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/mt.2013.141","article-title":"Myeloid\/microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease","volume":"21","author":"Sergijenko","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.07.001_bib41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/jgm.1305","article-title":"Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease","volume":"11","author":"Douillard-Guilloux","year":"2009","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omtm.2020.07.001_bib42","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1182\/blood-2009-11-252874","article-title":"Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype","volume":"115","author":"van Til","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2020.07.001_bib43","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/mt.2012.50","article-title":"The \u03b2-globin locus control region in combination with the EF1\u03b1 short promoter allows enhanced lentiviral vector-mediated erythroid gene expression with conserved multilineage activity","volume":"20","author":"Montiel-Equihua","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.07.001_bib44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.omtm.2019.05.015","article-title":"Enhancing lentiviral and alpharetroviral transduction of human hematopoietic stem cells for clinical application","volume":"14","author":"Schott","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2020.07.001_bib45","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/mt.2012.46","article-title":"Extensive methylation of promoter sequences silences lentiviral transgene expression during stem cell differentiation in\u00a0vivo","volume":"20","author":"Herbst","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.07.001_bib46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijpharm.2015.05.062","article-title":"Innovative approach in Pompe disease therapy: induction of immune tolerance by antigen-encapsulated red blood cells","volume":"491","author":"Cremel","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.omtm.2020.07.001_bib47","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1172\/JCI200419205","article-title":"Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells","volume":"113","author":"Biffi","year":"2004","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2020.07.001_bib48","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1172\/JCI28873","article-title":"Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice","volume":"116","author":"Biffi","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2020.07.001_bib49","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.omtm.2020.04.023","article-title":"Lentiviral hematopoietic stem cell gene therapy corrects murine Pompe disease","volume":"17","author":"Stok","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2020.07.001_bib50","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s13104-016-2118-z","article-title":"Lentiviral gene transfer into human and murine hematopoietic stem cells: size matters","volume":"9","author":"Cant\u00e9-Barrett","year":"2016","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.omtm.2020.07.001_bib51","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1182\/blood.V96.10.3392.h8003392_3392_3398","article-title":"High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors","volume":"96","author":"Salmon","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2020.07.001_bib52","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/sj.mt.6300251","article-title":"Functional analysis of various promoters in lentiviral vectors at different stages of in\u00a0vitro differentiation of mouse embryonic stem cells","volume":"15","author":"Hong","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.07.001_bib53","doi-asserted-by":"crossref","first-page":"e12413","DOI":"10.1371\/journal.pone.0012413","article-title":"Quantitative comparison of constitutive promoters in human ES cells","volume":"5","author":"Norrman","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2020.07.001_bib54","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/gt.2017.20","article-title":"Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells","volume":"24","author":"Hoffmann","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2020.07.001_bib55","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1089\/scd.2007.0084","article-title":"Promoter-dependent EGFP expression during embryonic stem cell propagation and differentiation","volume":"17","author":"Wang","year":"2008","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.omtm.2020.07.001_bib56","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/mt.2015.16","article-title":"Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice","volume":"23","author":"Dahl","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.07.001_bib57","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1074\/jbc.M404008200","article-title":"Lysosomal acid \u03b1-glucosidase consists of four different peptides processed from a single chain precursor","volume":"280","author":"Moreland","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"issue":"Suppl 1","key":"10.1016\/j.omtm.2020.07.001_bib58","first-page":"114","article-title":"New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond","volume":"12","author":"Kishnani","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.omtm.2020.07.001_bib59","doi-asserted-by":"crossref","first-page":"125358","DOI":"10.1172\/jci.insight.125358","article-title":"Improved efficacy of a next-generation ERT in murine Pompe disease","volume":"4","author":"Xu","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtm.2020.07.001_bib60","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid \u03b1-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.07.001_bib61","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1042\/BJ20050364","article-title":"Carbohydrate-remodelled acid \u03b1-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice","volume":"389","author":"Zhu","year":"2005","journal-title":"Biochem. J."},{"key":"10.1016\/j.omtm.2020.07.001_bib62","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1074\/jbc.M112.438663","article-title":"Glycosylation-independent lysosomal targeting of acid \u03b1-glucosidase enhances muscle glycogen clearance in Pompe mice","volume":"288","author":"Maga","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2020.07.001_bib63","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00109-017-1505-9","article-title":"Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease","volume":"95","author":"Yi","year":"2017","journal-title":"J.\u00a0Mol. Med. (Berl.)"},{"key":"10.1016\/j.omtm.2020.07.001_bib64","doi-asserted-by":"crossref","first-page":"287","DOI":"10.21037\/atm.2019.04.67","article-title":"Progress and challenges of gene therapy for Pompe disease","volume":"7","author":"Ronzitti","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.omtm.2020.07.001_bib65","doi-asserted-by":"crossref","first-page":"e24826","DOI":"10.1371\/journal.pone.0024826","article-title":"A new extensively characterised conditionally immortal muscle cell-line for investigating therapeutic strategies in muscular dystrophies","volume":"6","author":"Muses","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2020.07.001_bib66","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nbt1047","article-title":"Ex\u00a0vivo generation of fully mature human red blood cells from hematopoietic stem cells","volume":"23","author":"Giarratana","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2020.07.001_bib67","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/mt.2014.242","article-title":"Perforin gene transfer into hematopoietic stem cells improves immune dysregulation in murine models of perforin deficiency","volume":"23","author":"Carmo","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2020.07.001_bib68","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10545-011-9360-2","article-title":"Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases","volume":"35","author":"Manwaring","year":"2012","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2020.07.001_bib69","series-title":"Muscle Biopsy: A Practical Approach","author":"Dubowitz","year":"2013"}],"container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050120301509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050120301509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:52:59Z","timestamp":1778867579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050120301509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":69,"alternative-id":["S2329050120301509"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2020.07.001","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lentiviral Hematopoietic Stem Cell Gene Therapy Rescues Clinical Phenotypes in a Murine Model of Pompe Disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2020.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors.","name":"copyright","label":"Copyright"}]}}